Cancer care has long focused on what drugs to give and in what doses, but a growing body of evidence suggests the clock on ...

Imagine zipping across Alberta’s wide-open prairies under a sunset that sets the sky ablaze, the Rockies peeking out in the ...

DelveInsight's Pancreatic Cancer Market Insights report includes a comprehensive understanding of current treatment practices, ...

This important study reveals that mitotic release of an ER-microtubule tether is critical for normal mitotic progression. Manipulating CLIMP63 phosphorylation, the authors provide convincing evidence ...

Updated clinical data presented at ASH show robust efficacy, rapid onset of remission, high incidence of MRD1-negativity, and an encouraging survival signal with ICT01 in combination with azacitidine ...

New two- and three-year EPCORE® NHL-2 follow-up data evaluating epcoritamab in combination with standard of care regimens demonstrate remission in patients with DLBCL and FLLatest EPCORE DLBCL-3 trial ...

Bitcoin's (CRYPTO: BTC) signature four-year halving cycle, where market peaks follow 12–18 months after each halving, may be weakening or breaking entirely, according to top traders. The market is now ...

For over a decade, Bitcoin’s price marched to a predictable drumbeat: the four-year halving cycle. Each halving slashed miner rewards, triggered saupply shock, and ignited explosive bull runs followed ...

Has the bitcoin price truly broken from its historic four-year rhythm, or is global liquidity now dictating the pace of every major cycle? Analyzing BTC Growth Since Cycle Lows, we can see that ...

BitMEX co-founder Arthur Hayes has agreed that the four-year crypto cycle is dead, but not for the reasons most people believe. “As the four-year anniversary of this fourth cycle is upon us, traders ...

Bitcoin BTC $87,707.18 is unlikely to enter a bear market in the coming months as supportive monetary conditions are expected to prevail, effectively rendering the traditional four-year halving cycle ...

Takeda is tapping out of the cell therapy arena as part of a "strategic portfolio reprioritization," with 137 roles at the drugmaker's Massachusetts R&D site affected. The company is seeking a partner ...